Molecular-based precision oncology clinical decision making augmented by artificial intelligence

Emerg Top Life Sci. 2021 Dec 7:ETLS20210220. doi: 10.1042/ETLS20210220. Online ahead of print.


The rapid growth and decreasing cost of Next-generation sequencing (NGS) technologies have made it possible to conduct routine large panel genomic sequencing in many disease settings, especially in the oncology domain. Furthermore, it is now known that optimal disease management of patients depends on individualized cancer treatment guided by comprehensive molecular testing. However, translating results from molecular sequencing reports into actionable clinical insights remains a challenge to most clinicians. In this review, we discuss about some representative systems that leverage artificial intelligence (AI) to facilitate some processes of clinicians’ decision making based upon molecular data, focusing on their application in precision oncology. Some limitations and pitfalls of the current application of AI in clinical decision making are also discussed.

PMID:34874054 | DOI:10.1042/ETLS20210220

Source link

Back to top button